References
- World Health Organization. World Malaria Report 2015. [Accessed 2016, Feb 02]. http://www.who.int/malaria/publications/world-malaria-report-2015/en/.
- RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet (London, England) 2015;386:31–45. doi:10.1016/S0140-6736(15)60721-8. PMID:25913272.
- Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R, Shomari M, Leach A, Fernandes J, Dosoo D, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. The J Infect Dis. 2010;202:1076–87. doi:10.1086/656190. PMID:20735271
- European Medicines Agency – News and Events – First malaria vaccine receives positive scientific opinion from EMA [Accessed 2015 Oct 22]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_detail_002376.jsp&mid=WC0b01ac058004d5c1.
- Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec. 2016;91:33–51.
- MVI Malaria Vaccine Initiative. RTS,S. Ghana, Kenya, and Malawi to take part in WHO malaria vaccine pilot programme. [Accessed 2017 June 16]. http://www.malariavaccine.org/malaria-and-vaccines/first-generation-vaccine/rtss.
- World Health Organization. Hepatitis B vaccines: WHO position paper–recommendations. Vaccine. 2010;28:589–90. doi:10.1016/j.vaccine.2009.10.110. PMID:19896455
- Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000;355:561–5. doi:10.1016/S0140-6736(99)07239-6. PMID:10683019
- RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine. 2014;11:e1001685. doi:10.1371/journal.pmed.1001685. PMID:25072396
- White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15:1450–8. doi:10.1016/S1473-3099(15)00239-X. PMID:26342424
- Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, François N, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Pub Health. 2011;11:882. doi:10.1186/1471-2458-11-882.
- Madhi SA, Koen A, Jose L, van Niekerk N, Adrian PV, Cutland C, Francois N, Ruiz-Guinazu J, Yarzabal JP, Moreira M, et al. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine. 2017;96:e5881. doi:10.1097/MD.0000000000005881. PMID:28079828
- European Medicines Agency- Synflorix Product Information. 2016.
- World Health Organization. Pneumococcal vaccines WHO position paper – 2012 – Recommendations. Vaccine. 2012;30:4717–8. doi:10.1016/j.vaccine.2012.04.093. PMID:22621828
- Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O'Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS medicine. 2010;7:e1000348. doi:10.1371/journal.pmed.1000348. PMID:20957191
- Klugman KP, Madhi SA, Adegbola RA, Cutts F, Greenwood B, Hausdorff WP. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine. 2011;29:3372–3. doi:10.1016/j.vaccine.2011.02.089. PMID:21396901
- von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, Madhi SA, Zell ER, Verani JR, O'Brien KL, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014;371(20):1889–99. doi:10.1056/NEJMoa1401914. PMID:25386897
- Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC, Tumbo J, Van der Merwe CF, Delem A, De Vos B. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J Infect Dis. 2010;202(Supplement_1):S93–100. doi:10.1086/653550. PMID:20684724
- O'Ryan M, Lucero Y, Linhares AC. Rotarix®: vaccine performance 6 years postlicensure. Expert Rev Vaccines. 2011;10(12):1645–59. doi:10.1586/erv.11.152. PMID:22085167
- RTS, S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–95. doi:10.1056/NEJMoa1208394. PMID:23136909
- RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. T N Engl J Med. 2012;367(24):2284–95. doi:10.1056/NEJMoa1208394.
- European Medicines Agency. Mosquirix H-W-2300. Mosquirix: Product information. [Accessed 2017 August 04]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000395.jsp&mid=
- Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356–60. doi:10.1128/CVI.13.3.356-360.2006. PMID:16522777
- Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Giagn Lab Immunol. 1997;4:415–22.